Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up

A long-term follow-up (LTFU) of the nine-valent human papillomavirus (9vHPV) vaccine efficacy study in young women aged 16–26 years was initiated to evaluate if vaccine effectiveness for up to 14 years post-vaccination will remain above 90%. Vaccine effectiveness is measured as percent reduction in...

Full description

Bibliographic Details
Main Authors: Susanne K. Kjaer, Mari Nygård, Karin Sundström, Christian Munk, Sophie Berger, Mensur Dzabic, Katrin Elisabeth Fridrich, Marianne Waldstrøm, Sveinung Wergeland Sørbye, Oliver Bautista, Thomas Group, Alain Luxembourg
Format: Article
Language:English
Published: Taylor & Francis Group 2021-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
cervical intraepithelial neoplasia
effectiveness
human papillomavirus
long-term follow-up
vaccine
nine-valent human papillomavirus vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2020.1839292

Similar Items

Similar Items